[Quality of life of migraine patients after treatment with 2.5 mg oral naratriptan].
OBJECTIVE
The primary objective of this prospective, open, non controlled, multicenter study was to collect data on migraine patient's health related quality of life before and after treatment of their migraine attacks b naratriptan orl 2.5 mg over a 12 week period.


METHODS
The impact on health related quality of life was evaluated by the mean change from pre-treatment scores on the French migraine health related quality of life specific questionnaire (QVM).


RESULTS
244 patients have been included in the study. A statistically significant score improvement in health related quality of life, as measured by the global score and the four scores related to the four dimensions of the QVM questionnaire (functional, psychological, social and therapeutic) was observed compared to the pre-treatment score values. At the end of the treatment period, 67% of patients preferred naratriptan oral 2.5 mg to their usual treatment.


CONCLUSIONS
Those data suggest that the use of naratriptan oral 2.5 mg for the treatment of migraine attacks during a 12 week period may be associated with a significant improvement in migraine patient's quality of life.
Massiou
H
H
Service de Neurologie, Hôpital Lariboistère, Paris.
Valette
C
C
D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000523:psychology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life; D016896:Treatment Outcome; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*
D007211:Indoles; D010880:Piperidines; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C106783:naratriptan